SCHEMBL21297294

SCHEMBL21297294

CC(C)c1cccc(NC2COC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2D O15399 1/20 0.40
GRIN3B O60391 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2A Q12879 1/20 0.40
GRIN2B Q13224 1/20 0.40
GRIN2C Q14957 1/20 0.40
GRIN3A Q8TCU5 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
CCNT1 O60563 1/20 0.39
CDK9 P50750 1/20 0.39
FADS1 O60427 1/20 0.38
KIF11 P52732 1/20 0.38
CA2 P00918 2/20 0.37
RXFP1 Q9HBX9 1/20 0.36
IDO1 P14902 1/20 0.36
ICMT O60725 1/20 0.35
HDAC4 P56524 2/20 0.35
HDAC8 Q9BY41 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MDM4 O15151 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18672877 0.88 BACE1 (0.39) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL12615267 0.84 GRIN2D (0.43) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL12963661 0.84 PRMT5 (0.40) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL24506826 0.81 RXFP1 (0.42) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
Hydrochloric Acid SCHEMBL5234332 0.79 RXFP1 (0.46) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL20045019 0.78 CCR2 (0.35) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL20252397 0.78 CCR2 (0.35) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL23251064 0.78 HTR6 (0.47) GRIN2DGRIN3BGRIN1GRIN2AGRIN2B
SCHEMBL15830058 0.77 HSD17B10 (0.46) ALDH1A1TP53CYP3A4MAPTHPGD
SCHEMBL25583705 0.76 POLB (0.50) CDK9KIF11KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 EP disclosed
US-10391089-B2 PRMT5 inhibitors and uses therof Epizyme, Inc. (US) 2019-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10391089-B2 PRMT5 inhibitors and uses therof PRMT5, PRMT1, PRMT6 GRIN2D 2794/4885GRIN3B 1386/4885GRIN1 590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.